OTC:TCBPY
TC BioPharm (Holdings) plc
A clinical-stage biopharmaceutical entity with a significant cash burn rate funded by equity issuances and no current operating revenue.
Key Metrics
Investment Thesis
Bull Case
The company possesses valuable early-stage intellectual property with significant non-cash adjustments suggesting potential future asset recognition or restructuring benefits. Investors may be attracted by the substantial paid-in capital of $41.1M which provides a runway for advancing assets without immediate dilution if financing markets remain favorable.
Bear Case
The business model is unsustainable in its current form with zero revenue and a massive operating loss exceeding $14M before non-operating gains. The working capital deficit and high interest expense of $83k on limited cash reserves present an existential threat without successful near-term financing or product approvals.
About TC BioPharm (Holdings) plc
TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates. The company operates primarily in the United States, with R&D activities aimed at advancing its pipeline to address unmet medical needs. Currently, the firm relies on non-operating income and financing activities rather than product revenue.
Analysis
Management Discussion
The company reported a net loss of $5.9M driven by substantial research and development costs of $7.8M and general administrative expenses of $6.5M. Despite generating non-operating income of $7.2M, the firm's cash position decreased by $2.3M to $2.5M, indicating a critical need for continued capital raising to sustain its pipeline.
Industry Overview
The biopharmaceutical industry is characterized by high barriers to entry, long development cycles, and significant regulatory hurdles that require substantial capital investment. Companies in this space often operate at a loss for years while conducting clinical trials before achieving commercial viability and generating revenue.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Operating Expenses | $14.2M |
| Operating Income | $-14.2M |
| R&D | $7.8M |
| G&A | $6.5M |
| Stock-Based Comp | $444.5K |
| Depreciation | $596.7K |
| Amortization | $36.3K |
| Other OpEx | $0 |
| Non-Operating Income | $7.2M |
| Interest Expense | $83.0K |
| Pre-Tax Income | $-7.0M |
| Income Tax | $-1.1M |
| Continuing Ops | $-5.9M |
| Discontinued Ops | $0 |
| Net Income | $-5.9M |
| Minority Interest | $0 |
| Net to Common | $-5.9M |
| Metric | 2023 |
|---|---|
| Current Assets | $5.7M |
| Cash & Equivalents | $2.5M |
| Prepaid Expenses | $2.2M |
| Other Current Assets | $1.0M |
| Long-Term Assets | $3.2M |
| PP&E (Net) | $1.3M |
| Intangibles | $615.2K |
| Operating Leases | $1.3M |
| Other LT Assets | $0 |
| Total Assets | $8.9M |
| Current Liabilities | $4.8M |
| Current Leases | $305.3K |
| Other Current Liab | $3.2M |
| Long-Term Liabilities | $1.5M |
| LT Operating Leases | $1.5M |
| Other LT Liab | $0 |
| Total Liabilities | $6.2M |
| Shareholders' Equity | $2.7M |
| Paid-In Capital | $41.1M |
| Retained Earnings | $-38.8M |
| Total L&E | $8.9M |
| Metric | 2023 |
|---|---|
| Net Income (CFO) | $-5.9M |
| Non-Cash Adjustments | $-7.9M |
| Working Capital Changes | $3.2M |
| Cash from Operations | $-10.5M |
| Capital Expenditures | $110.4K |
| Cash from Investing | $-208.8K |
| Cash from Financing | $8.5M |
| FX Effect | $-112.2K |
| Net Change in Cash | $-2.3M |
| Beginning Cash | $4.8M |
| Ending Cash | $2.5M |
Frequently Asked Questions
How does TC BioPharm (Holdings) plc make money?
Research and Development (driving the majority of expenses at $7.8M), Non-Operating Income/Loss (generating $7.2M in other income), and Financing Activities (raising capital through share issuances).
What are the main risks for TCBPY?
Significant cash burn of $10.5M from operations without revenue generation, heavy reliance on equity financing which dilutes shareholders, potential failure of clinical trials leading to asset write-downs, and limited current liquidity reserves compared to annual operating expenses.
What is TCBPY's competitive advantage?
Access to external funding sources for high-risk R&D, specialized scientific talent in a niche therapeutic area, and a streamlined corporate structure designed for rapid preclinical advancement.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.